Metafora Biosystems

Metafora’s platform measures single-cell metabolism changes, the foundation of life. The company develops products for in vitro diagnostics and cell therapy using its METAbolism platform.

METAflow uses AI to simplify flow and mass cytometry data analysis, reducing the need for technical expertise and providing an intuitive dashboard for results.

METAglut1 is an in vitro blood test for diagnosing GLUT1 deficiency syndrome in children and adults.

METAglut1 is a rapid and reliable blood test for early diagnosis of GLUT1 deficiency syndrome, a treatable rare disease causing irreversible neurological issues.

Metafora and Cerba HealthCare Group collaborate to integrate Metafora’s metabolomics technology into diagnostics. The platform assesses cellular energy needs in relation to patient health.

Metafora, AP-HP, and Cerba HealthCare announced findings from a validation study at the 3rd European Conference on GLUT1 Deficiency.

Metafora combines life sciences expertise with advanced analytics to develop diagnostic tests while complying with healthcare regulations. The company’s multidisciplinary team includes entrepreneurs, cell biologists, and mathematicians.

Metafora applies single-cell analysis, metabolism expertise, and AI to accelerate insights and improve health. Its products include IVD and cell therapy reagents.

Metafora’s METAflow software suite automates flow cytometry data analysis with AI-driven cell clustering and an intuitive interface for high-quality results.

Metafora Biosystems develops **METAflow**, an AI-powered cloud platform that automates analysis of flow cytometry data, addressing inefficiencies in manual processing. The company, founded in 2011, partners with the **EIC Accelerator** to advance METAflow into a clinical-grade digital solution. Flow cytometry data analysis is currently slow, complex, and difficult to scale, creating demand for automated tools like METAflow.

Sep 2026eiceuNews article

Researchers develop a rapid blood test for **Glut1 deficiency syndrome (De Vivo disease)**, a rare but treatable neurometabolic disorder. The test, validated through collaboration between **AP-HP, METAFORA biosystems, the Institute of Molecular Genetics of Montpellier, Cerba Healthcare, and 30+ centers**, allows for early detection. Professor Fanny Mochel at **Paris Brain Institute** led the effort, ensuring reliability and speed in diagnosis.

Jun 2023Medical XpressNews article

METAFORA biosystems receives a recommendation from France’s Haute Autorité de Santé (HAS) for insurance coverage of its **METAglut1™** test, designed for the early diagnosis of **De Vivo disease (GLUT1 deficiency syndrome)**, a rare neurometabolic disorder. The decision supports broader patient access to this diagnostic tool in France.

May 2023BioSpaceNews article

Metafora Biosystems introduces **METAflow**, a cloud-based software platform designed for digital flow cytometry analysis. The tool aims to streamline data processing in immunology and cell biology research. The company highlights its focus on accelerating workflows for laboratories using high-throughput cytometry techniques.

Jun 2022ActuIANews article